Preventing relapse after stem cell transplant for high-risk MDS
Part of Blood & lymphatic clinical trials.
This trial tests whether giving medication after a donor stem cell transplant can prevent the return of very high-risk myelodysplastic syndrome (MDS). It is for people who have a suitable donor and are healthy enough for the procedure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with very high-risk MDS using a scoring system called IPSS-M.
- You have a stem cell donor who is a good match (related donor at least half-match, unrelated donor at least 80% match).
- You are generally healthy with good liver, kidney, heart, and lung function.
- You are able to give written informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether two drugs, Selinexor and Venetoclax, can help prevent leukemia or MDS from coming back after a stem cell transplant. It is for people who are at high risk of relapse and have recently had a transplant.
This trial tests a special type of donor immune cell (depleted of CD45RA cells) to see if it can prevent serious viral infections in people at high risk after a stem cell transplant from a half-matched donor.
This trial checks if using advanced tests to find leftover cancer cells before a stem cell transplant can help prevent the disease from coming back. If you have a myeloid blood cancer, you might be able to join.
This trial tests an injection of donor-derived immune cells (called RC1012) to lower the chance of AML coming back after an allogeneic stem cell transplant. It is aimed at people at higher risk of relapse once the transplant is completed.
This trial tests whether the drug interferon alfa can help prevent blood cancer from coming back after a stem cell transplant. It is for people with certain types of blood cancer (MDS or AML with a TP53 mutation) who had no detectable cancer cells when checked after transplant.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
Hear when a new Myelodysplastic Syndromes, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.